Status:
COMPLETED
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Lead Sponsor:
Innate Pharma
Conditions:
Smoldering Multiple Myeloma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
Detailed Description
This is a randomized Phase II, open label, multi-centre study, with two independent arms. Patients receive 6 injections of IPH2101, at the dose of 0.2 mg/kg or 2 mg/kg (according to their randomizati...
Eligibility Criteria
Inclusion
- SMM of any risk level according to a definition derived of the International Myeloma Working Group definition ( Br J Haematol 2003; 121: 749) : Serum M protein ≥ 3 g/dl , AND/OR Bone Marrow plasma cells ≥ 10 % with no evidence of end-organ damage (CRAB)
- (C)Absence of hypercalcemia : Ca \< 10.5 mg/dl
- (R)Absence of renal failure : creatinine \< 2mg/dl (177 μmol/l) or calculated creatinine clearance(according to MDRD) \> 50 ml/min
- (A)Absence of anemia : Hb \> 11 g/dl
- (B)Absence of lytic bone lesion on standard skeletal survey (MRI could be used if clinically indicated)
- Measurable disease defined as a disease with a serum M protein ≥ 1 g/dl
- No evidence of fatigue, recurrent infections or any clinical suspicion of MM
- Diagnosis of SMM confirmed on two consecutive assessments (ie fluctuation under 25% of serum protein level) performed with at least a 4 week interval.
- Age \> 18 years or \< 75 years
- ECOG performance status of 0 or 1
- Male or female patient who accepts and is able to use recognised effective contraception (oral contraceptives, IUCD, barrier method of contraception in conjunction with spermicidal jelly) throughout the study when relevant
- Informed consent signed by the patient
Exclusion
- Previous treatment having a proven or potential impact on myelomatous cells proliferation or survival (including IMiDs or proteasome inhibitors, conventional chemotherapies within the last 5 years, steroids within the last month prior to enrolment). Previous bisphosphonates started less than 3 months prior to enrolment.
- Use of any investigational agent within the last 3 months
- Clinical laboratory values at screening
- Platelet \< 75 x 10\^9 /l
- ANC \< 1.5 x 10\^9 /l
- Bilirubin levels \>1.5 ULN ; ALT and AST \> 3 ULN (grade 1 NCI)
- Primary or associated amyloidosis
- Abnormal cardiac status with any of the following
- NYHA stage III or IV congestive heart failure
- myocardial infarction within the previous 6 months
- symptomatic cardiac arrhythmia requiring treatment or persisting despite appropriate treatment
- Current active infectious disease or positive serology for HIV, HCV or positive Hbs Antigen
- History of or current auto-immune disease
- History of other active malignancy within the past five years (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma).
- Serious concurrent uncontrolled medical disorder
- History of allograft or solid organ transplantation
- Pregnant or lactating women
- Any condition potentially hampering compliance with the study protocol and follow-up schedule
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01222286
Start Date
September 1 2010
End Date
January 1 2013
Last Update
May 9 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
2
Mount Sinai School of Medicine
New York, New York, United States, 10029
3
Ohio State University
Columbus, Ohio, United States, 43210
4
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104